Patents by Inventor Xuchu Que

Xuchu Que has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids
    Patent number: 12209119
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: April 13, 2023
    Date of Patent: January 28, 2025
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury
    Patent number: 11897969
    Abstract: The disclosure provides for methods and treatments of ischemic injury, reperfusion injury, stroke and myocardial infarctions by administering within minutes to hours an antibody or antibody fragment that bind to and inhibits the biological activity of OxPL in an affected tissue.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: February 13, 2024
    Assignee: The Regents of the University of California
    Inventors: Sotirios Tsimikas, Joseph L. Witztum, Xuchu Que
  • THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS
    Publication number: 20230357374
    Abstract: The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
    Type: Application
    Filed: October 20, 2022
    Publication date: November 9, 2023
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS
    Publication number: 20230357376
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Application
    Filed: April 13, 2023
    Publication date: November 9, 2023
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Antibodies to oxidized phospholipids
    Patent number: 11655288
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 23, 2023
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Therapies and methods to treat TLR2-mediated diseases and disorders
    Patent number: 11530259
    Abstract: The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: December 20, 2022
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES
    Publication number: 20220135704
    Abstract: The disclosure provides for single chain variable fragments to MAA-oxidized specific epitopes (OSEs). The disclosure also provides single chain variable fragments that bind to MDA-OSEs or MAA-OSEs on oxidized phospholipids and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 5, 2022
    Inventors: Sotirios Tsimikas, Joseph Witztum, Xuchu Que
  • Antibodies to oxidation-specific epitopes
    Patent number: 11168148
    Abstract: The disclosure provides for single chain variable fragments to MAA-oxidized specific epitopes (OSEs). The disclosure also provides single chain virable fragments that bind to MDA-OSEs or MAA-OSEs on oxidized phospholipids and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 9, 2021
    Assignee: The Regents of the University of California
    Inventors: Sotirios Tsimikas, Joseph Witztum, Xuchu Que
  • INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY
    Publication number: 20210221916
    Abstract: The disclosure provides for methods and treatments of ischemic injury, reperfusion injury, stroke and myocardial infarctions by administering within minutes to hours an antibody or antibody fragment that bind to and inhibits the biological activity of OxPL in an affected tissue.
    Type: Application
    Filed: October 26, 2018
    Publication date: July 22, 2021
    Inventors: Sotirios Tsimikas, Joseph L. Witztum, Xuchu Que
  • THERAPIES AND METHODS TO TREAT TLR2-MEDIATED DISEASES AND DISORDERS
    Publication number: 20210155679
    Abstract: The disclosure provides for methods and treatments of TLR2-mediated diseases and disorders comprising administering an antibody, antibody fragment, or polypeptide that binds to and inhibits the biological activity of oxidized phospholipids.
    Type: Application
    Filed: January 29, 2019
    Publication date: May 27, 2021
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Antibodies to oxidized phospholipids
    Patent number: 11008382
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • Antibodies to oxidized phospholipids
    Patent number: 11008381
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: May 18, 2021
    Assignee: The Regents of the University of California
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES
    Publication number: 20190225709
    Abstract: The disclosure provides for single chain variable fragments to MAA-oxidized specific epitopes (OSEs). The disclosure also provides single chain virable fragments that bind to MDA-OSEs or MAA-OSEs on oxidized phospholipids and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 25, 2019
    Inventors: Sotirios Tsimikas, Joseph Witztum, Xuchu Que
  • ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS
    Publication number: 20180334498
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Application
    Filed: May 29, 2018
    Publication date: November 22, 2018
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS
    Publication number: 20180334497
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Application
    Filed: May 29, 2018
    Publication date: November 22, 2018
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS
    Publication number: 20180265576
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Application
    Filed: May 29, 2018
    Publication date: September 20, 2018
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que
  • ANTIBODIES TO OXIDIZED PHOSPHOLIPIDS
    Publication number: 20150376268
    Abstract: The disclosure provides for single chain variable fragments to oxidized phospholipid epitopes and methods of use thereof, including the production of transgenic animal models and the use of the fragments as therapeutic agents for treating CAS.
    Type: Application
    Filed: February 25, 2014
    Publication date: December 31, 2015
    Inventors: Joseph L. Witztum, Sotirios Tsimikas, Xuchu Que